



THE DAY TRADING ACADEMY
—SUCCESS WEALTH FREEDOM—
Let's Create Your Lifestyle

October 19th 2014 – Invest With Sarepta Therapeutics – By Jeffrey Hagenmeier



As the Ebola virus continues to spread in West Africa and in some rare cases beyond, medical researchers rush to bring to market, medicines that will help combat the disease. Of course, a vaccine is the ideal answer, but that is still illusive at this point. This past Thursday **Sarepta Therapeutics** announced that in two clinical studies involving its Ebola treatments, that there

was no evidence for concern in the drug candidates. That is there was no adverse reaction in the toxicology report.

As a result, in the pre-market trade on Friday, shares in the company advanced over 10%. The stock opened up at \$24.74 USD. The stock then surged to a high of **\$24.95 USD** (United States Dollar) at the beginning of regular market hours in New York. This was an additional 10% advance at the opening bell. The low for the day was **\$22.16 USD**. By the end of the day the stock was actually down and settled in at **\$22.22 USD**. The share price posted an actual .08% loss or 0.36% lower.

Sarepta Therapeutics is a medical research and drug development company founded in 1980 and located in Cambridge Massachusetts (It also has a laboratory in Oregon). Sarepta has 150 patents pending and has been issued over 170 patents as of 2008.

The primary products of the company at present are Morpholino oligomers (PMOs). In addition to a wide use in other illnesses, Morpholinos have been used in clinical studies to inhibit replication of a wide variety of single stranded RNA viruses. These would include Calicivirus, dengue fever, Hepatitis C, influenza, SARS, West Nile Virus and most importantly at present **Ebola**.

Market capitalization for the company is \$910 million USD. The stock began the week at \$18.78 USD. By the end of the week the share price for the company had increased \$3.44 an increase of 18.32%. For the year, the 52 week low was \$12.12 and the high reached \$44.29 a share. Volume on Friday was over 3.9 million shares traded. Average volume over the last 3 months has been 1.295 million.

The big news last week was that in Phase I human trials involving 30 subjects each the drug was well tolerated at varying dose levels. In earlier trials with monkeys, the drug offered protection against the Ebola virus ranging from 60% to 80% and 80% to 100% for the Marburg virus according to the company. The studies are being performed under a contract with the United States Department of Defense.

Considering that cases of new infection could rise to 10,000 a week with mortality rates reaching 70% in West Africa, there will be renewed calls for treatments and medications to halt the spread of the disease. In addition, to the United



THE DAY TRADING ACADEMY
—SUCCESS WEALTH FREEDOM—
Let's Create Your Lifestyle

States and Spain there is a general fear that the virus will spread to Latin America and Asia, which will be less able to deal with the spreading contagion.

The United States and other nations are sending medical personnel and soldiers to West Africa to help those nations most affected by the Ebola virus. They will help treat the sick and attempt to prevent an even larger breakout. The availability of new drugs in the treatment of Ebola are therefore, very much in demand. New pressure will be placed on the FDA (Food and Drug Administration) in the United States and comparable agencies in other countries, to speed approval of these types of medications and possible vaccines.

An investor can have confidence that the companies which can successfully offer hope and actual delivery of therapies and medications, will do well. Under these circumstances, one can safely assume that a target for the share price of Sarepta Therapeutics can be set for at least a minimum of **\$26.00 USD**. That will be a **20% increase** over the price in the stock market at present.